


Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 1 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

10165-042-999

APPLICATION NO.

10/573,905

APPLICANT

Coleman et al.

FILING DATE

May 30, 2006

ART UNIT

1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	4,343,782	8/10/982	Shapiro	
	A02	4,377,513	03/22/83	Sugimoto et al.	
	A03	4,658,019	04/14/87	Kung et al.	
	A04	4,703,008	10/27/87	Lin	
	A05	4,806,524	02/21/89	Kawaguchi et al.	
	A06	4,835,260	05/30/89	Shoemaker	
	A07	4,992,419	2/12/91	Woog et al.	
	A08	5,194,596	3/16/93	Tischer et al	
	A09	5,278,065	6/11/94	D'Andrea	
	A10	5,292,654	3/08/94	Yoshimura	
	A11	5,350,836	9/27/94	Kopchick et al.	
	A12	5,457,089	10/10/95	Fibi et al.	
	A13	5,547,933	08/20/96	Lin	
	A14	5,571,787	11/05/96	O'Brien et al.	
	A15	5,604,198	2/18/97	Poduslo et al.	
	A16	5,614,184	03/25/97	Sytkowski et al.	
	A17	5,618,698	04/08/97	Lin	
	A18	5,621,080	04/15/97	Lin	
	A19	5,625,035	04/29/97	Clemons	
	A20	5,661,125	08/26/97	Strickland	
	A21	5,696,080	12/09/97	O' Brien	
	A22	5,700,909	12/23/97	O'Brien	
	A23	5,714,459	02/03/98	O'Brien	
	A24	5,750,376	5/12/98	Weiss et al.	
	A25	5,756,349	05/26/98	Lin	
	A26	5,763,198	6/09/98	Hirth et al	
	A27	5,767,078	06/16/98	Johnson et al.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 2 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
10165-042-999

APPLICATION NO.
10/573,905

APPLICANT
Coleman et al.

FILING DATE
May 30, 2006

ART UNIT
1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A28	5,773,569	06/30/98	Wrighton et al.	
	A29	5,824,672	10/20/98	Simpkins et al.	
	A30	5,830,851	11/03/98	Wrighton et al.	
	A31	5,835,382	11/10/98	Wilson et al.	
	A32	5,856,298	01/05/99	Strickland	
	A33	5,888,772	03/30/99	Okasinski et al.	
	A34	5,955,422	09/21/99	Lin	
	A35	5,997,865	12/7/99	Bennett et al.	
	A36	6,048,971	4/11/00	Sytkowski et al.	
	A37	6,071,970	6/06/00	Mueller et al.	
	A38	6,103,526	04/15/05	Smith et al.	
	A39	6,153,407	11/28/00	Sytkowski et al.	
	A40	6,165,783	12/26/00	Weiss et al.	
	A41	6,242,570	6/05/01	Sytkowski	
	A42	6,291,661	09/18/01	Graddis et al.	
	A43	6,340,742	1/22/02	Burg et al.	
	A44	6,399,336	6/4/02	Paulson et al.	
	A45	6,440,932	8/27/02	Lehmann et al.	
	A46	6,489,293	12/3/02	Sytkowski et al.	
	A47	6,521,245	2/18/03	Zaharia	
	A48	6,531,121	3/11/03	Brines et al.	
	A49	6,583,272	6/24/03	Bailon	
	A50	6,645,522	11/11/03	Naeff et al.	
	A51	7,214,532	5/08/07	Stern et al.	
	A52	7,309,687	12/18/07	Brines et al.	
	A53	7,345,019	3/18/08	Brines et al.	
	A54	2002/0031806	3/14/02	Lee	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 3 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
10165-042-999

APPLICATION NO.
10/573,905

APPLICANT
Coleman et al.

FILING DATE
May 30, 2006

ART UNIT
1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A55	2002/0052309	5/02/02	Anagnostou et al.	
	A56	2002/0061849	5/23/02	Nielsen et al.	
	A57	2002/0077294	6/20/02	Kay et al.	
	A58	2002/0081734	6/27/02	Choi et al.	
	A59	2002/0086816	7/04/02	Brines et al.	
	A60	2002/0142370	10/3/02	Paulson et al.	
	A61	2002/0160460	10/31/02	Paulson et al.	
	A62	2003/0003529	1/2/03	Bayer	
	A63	2003/0040037	2/27/03	Bayer	
	A64	2003/0072737	4/17/03	Brines	
	A65	2003/0077753	4/24/03	Tischer	
	A66	2003/0083251	5/01/03	Westfenfelder	
	A67	2003/0104988	6/5/03	Brines	
	A68	2003/0113871	6/19/03	Lee et al.	
	A69	2003/0118547	6/26/03	Vandenberg	
	A70	2003/0120045	6/26/03	Bailon	
	A71	2003/0124115	7/3/03	Lee et al.	
	A72	2003/0134798	7/17/03	Brines et al.	
	A73	2003/0166566	9/04/03	Kinstler et al.	
	A74	2004/0009902	1/15/04	Boime	
	A75	2004/0018978	1/29/04	Campana et al.	
	A76	2004/0091961	5/13/04	Evans et al.	
	A77	2004/0096447	5/20/04	Yasuda et al.	
	A78	2004/0122216	6/24/04	Nielsen et al.	
	A79	2004/0209812	10/21/04	Farrell et al.	
	A80	2004/0214236	10/28/04	Brines et al.	
	A81	2005/0176627	8/11/05	Cerami et al.	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 4 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A82	2006/0034799	2/16/06	Brines et al.	
	A83	2006/0216757	9/28/06	Brines et al.	
	A84	2007/0298031	12/27/07	Brines et al.	
	A85	2008/0045412	02/21/08	Brines et al.	
	A86	09/290,938	4/13/99	Brines et al.	
	A87	09/547,220	4/11/00	Brines et al.	
	A88	09/718,829	11/21/00	Brines et al.	
	A89	09/716,963	11/21/00	Brines et al.	
	A90	09/716,960	11/21/00	Brines et al.	
	A91	10/554,517	10/25/05	Brines et al.	
	A92	11/283,024	11/18/05	Cerami et al.	
	A93	11/631,458	7/01/05	Brines et al.	
	A94	11/880,275	7/19/07	Brines et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	CA 2,294,448	12/30/98	Roche Diagnostics Gmbh		
	B02	DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		
	B03	EP 555880	8/18/93	Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp.		
	B04	EP 0640619	1/03/95	Amgen Inc.		
	B05	EP 0668 351	8/23/95	Amgen, Inc.		
	B06	EP 1064951	1/03/01	F. Hoffmann-La Roche AG		
	B07	JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
	B08	JP 5-246885	09/24/93	JP-A Kokai (w/English Translation & Certificate of Translation)		

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B09	WO 00/032772	6/8/00	Eli Lilly & Co.		
	B10	WO 00/061164	10/19/00	Kenneth S. Warren Laboratories		
	B11	WO 00/24893	5/4/00	Amgen, Inc.		
	B12	WO 00/35475	06/22/00	Ehrenreich, Hannelore (w/English abstract)		
	B13	WO 01/02017	1/11/01	F. Hoffmann-La Roche AG		
	B14	WO 01/81405	1/11/01	Amgen Inc.		
	B15	WO 01/82952	11/08/01	Action Pharma APS		
	B16	WO 01/82953	11/08/01	Action Pharma APS		
	B17	WO 01/87329	11/22/01	F. Hoffmann-La Roche AG		
	B18	WO 02/053580	7/11/02	Kenneth S. Warren Institute, Inc.		
	B19	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		
	B20	WO 02/14356	2/21/02	Althoff, Claudia		
	B21	WO 02/49673	6/27/02	F. Hoffmann-La Roche AG		
	B22	WO 03/029291	4/10/03	F. Hoffmann-La Roche AG		
	B23	WO 04/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B24	WO 04/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
	B25	WO 04/022577	3/18/04	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
	B26	WO 04/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
	B27	WO 04/112693	12/29/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B28	WO 05/025606	3/24/05	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
	B29	WO 05/032467	4/14/05	Warren Pharmaceuticals, Inc.		
	B30	WO 05/084364	9/15/05	The Kenneth S. Warren Institute, Inc.		
	B31	WO 05/117927	12/15/05	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B32	WO 06/002646	1/12/06	Lundbeck A/S		
	B33	WO 06/014349	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 6 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B34	WO 06/014466	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S		
	B35	WO 91/05867	5/02/91	Amgen Inc.		
	B36	WO 92/08493	5/29/92	Brigham & Women's Hospital		
	B37	WO 94/09257	4/28/94	Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract)		
	B38	WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B39	WO 95/05465	02/23/95	Amgen, Inc.		
	B40	WO 96/14081	5/17/96	Boehringer Mannheim GMBH		
	B41	WO 97/08307	3/6/97	Il Dong Pharmaceutical Co. Ltd.		
	B42	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd. (W/English abstract)		
	B43	WO 97/32895	9/12/97	Regents of the University of California		
	B44	WO 98/10650	3/19/98	East Carolina University		
	B45	WO 98/18926	05/07/98	G.D. Searle & Co.		
	B46	WO 98/58660	12/30/98	Boehringer Mannheim GMBH (w/English abstract)		
	B47	WO 95/31560	11/23/95	Transkaryotic Therapies, Inc.		
	B48	WO 94/12650	6/9/94	Transkaryotic Therapies, Inc.		
	B49	WO 93/09222	5/13/93	Transkaryotic Therapies, Inc.		
	B50	WO 93/25221	12/23/93	Alkermes Controlled Therapeutics		
	B51	WO 91/09955	7/11/91	Applied Research Systems, ARS Holding MV		
	B52	WO 91/06667	5/16/91	Cell Genesys, Inc.		
	B53	WO 90/11354	10/4/90	Institut Pasteur (w/English abstract)		
	B54	WO 86/03520	6/19/86	Genetics Insitute, Inc.		
	B55	WO 85/02610	6/20/85	Kirin-Amgen, Inc.		
	B56	WO 99/21966	5/06/99	Neurospheres Holdings Ltd.		

EXAMINER
NY1-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper 1, Declaration, Brines clean copy of claims, and Ehrenreich clean copy of claims (10/02/06)	
	C02	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia," Shock, Vol. 22(1), pp 63-69	
	C03	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134	
	C04	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant alpha-crystallins," Current Eye Research, Vol. 18:270-276	
	C05	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C06	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc. Natl. Acad. Sci. USA 91:3974-3978	
	C07	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C08	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie der Demenz," Arzneiverordnung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
	C09	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol., 50:287-291.	
	C10	AY et al., 1999, "Potential usefulness of basic fibroblast growth factor as a treatment for stroke," Cerebrovascular Disease, Vol. 9:131-135	
	C11	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits," Pediatric Res., Vol. 40(3):381-387	
	C12	BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic activity," Blood , Vol. 98(11, part 2):132b-133b Abstract 4193	
	C13	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol. Cell. Biol. 14(10):6506-6514	
	C14	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships," J. Biol. Chem. 272(8):4985-4992	
	C15	BARRON et al., 1994, "Alternatively spliced mRNAs encoding soluble isoforms of the erythropoietin receptor in murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8	
	C16	BASKAYA et al., 1997, "The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats," Neuroscience Letters, Vol. 226:33-36	
	C17	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12.	
	C18	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res. Commun. 164(2):788-795	
	C19	BELAYEV et al., 1996, "Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats," Brain Research, Vol. 739:88-96	
	C20	BENIT et al., 1993, "The 'WS motif' common to v-mpl and members of the cytokine receptor superfamily is dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8787-790	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C21	BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598	
	C22	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C23	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57	
	C24	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C25	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C26	BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin," New England Journal of Medicine, Vol. 339(9):584-590	
	C27	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828	
	C28	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22	
	C29	BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7	
	C30	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-15993	
	C31	BOADO et al., 1998, " Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15.	
	C32	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562	
	C33	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16	
	C34	BONDY, 1995, "Minireview -- The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345	
	C35	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559	
	C36	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972	
	C37	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388.	
	C38	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531	
	C39	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS). Title, Date, Pertinent Pages, Etc.)	T
	C40	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597.	
	C41	BUEMI et al., 2002, "Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm Venereol., Vol. 82:411-417	
	C42	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," The Journal of Histochemistry (Abstract) www.jhc.org/cgi.contents/abstract/29/3/331	
	C43	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C44	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
	C45	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401	
	C46	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325	
	C47	CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. Vol. 114(6):1149-58.	
	C48	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol Brain Res, Vol. 81, pp. 29-42	
	C49	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C50	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C51	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C52	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C53	CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science, Vol. 244:1081-1085	
	C54	CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," Arthritis & Rheumatism, Vol. 52(3):940-950	
	C55	D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243	
	C56	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960	
	C57	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature, Vol. 415, pp. 175-179	
	C58	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biology of the Neonate, 79(304):228-35	
	C59	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687	

EXAMINER
NY1-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE May 30, 2006	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C60	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7	
	C61	DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318	
	C62	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immunol Methods, Vol. 89:271-277	
	C63	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C64	STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C65	DIEM et al., 2005, "Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385	
	C66	DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360	
	C67	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain," Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C68	DIPAULO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C69	DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957	
	C70	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78	
	C71	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C72	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299.	
	C73	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C74	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263(33):17516-17521.	
	C75	ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55	
	C76	EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13	
	C77	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C78	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54	
	C79	EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185	
	C80	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C81	EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," Transplantation Proceedings, Vol. 36, pp. 2935-2938	
	C82	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> ," Proc. Natl. Acad. Sci. U. S. A. 100(11):6741-6	
	C83	ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org , July 2006	
	C84	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C85	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C86	FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," PNAS, Vol. 103(46):17531-17536	
	C87	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C88	FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C89	FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov/CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htm	
	C90	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C91	FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," Am Heart Journal. Vol. 101(5): 593-600	
	C92	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," J. of Clinical Endocrinology and Metabolism, Vol. 78(3):753-756	
	C93	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action--it takes two to tango, but how?" Endocrinology 143(1):2-10	
	C94	FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983	
	C95	FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," J. Controlled Release, Vol. 46:117-28	
	C96	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," American Journal of Kidney Disease, Vol. 26(1), pp. 202-8	
	C97	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," Lukemia, 11 Supl 3, pp. 444-5	
	C98	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73(1):84-89.	
	C99	FUNG et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2:119-128	
	C100	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," J. of Biological Chemistry, Vol. 269(10):7224-7230	
	C101	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," Stroke, Vol. 27(4):761-765	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C102	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	
	C103	GENBANK No. M59941, 1994	
	C104	GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer. Chem Soc., Vol. 124(4):544-555	
	C105	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Actio," Methods in Enzymology, Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121.	
	C106	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206.	
	C107	GOLDWASSER et al., 1975, "An Assay for Erythropoietin <i>in Vitro</i> at the Milliunit Level," Endo., 97(2):315-323.	
	C108	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455	
	C109	GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury," PNAS, Vol. 102(45):16379-84	
	C110	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 99(8):5627-5631	
	C111	GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy," Pharm. Ther. Vol. 80(2):123-147	
	C112	GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP therapy. J Sleep Res. 4(S1): 130-134	
	C113	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-x _L expression", Blood 94:87-96	
	C114	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. 38:480-486	
	C115	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration," Nature Medicine, Vol. 8(7):718-724	
	C116	GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta. 1592:215-223	
	C117	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo," J. Biol. Chem. Vol. 277(31):27581-27584	
	C118	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar granule cells," Toxicological Sciences, Vol. 64:83-89	
	C119	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527.	
	C120	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066	
	C121	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and Bioengineering, Vol. 16:1069-1079	
	C122	HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b	
	C123	HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209	
	C124	HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366	
	C125	HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319	
	C126	HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS	
	C127	HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594	
	C128	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C129	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156	
	C130	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C131	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C132	HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6	
	C133	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6.	
	C134	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357	
	C135	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C136	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients," Nephron, Vol. 72, pp. 30-36	
	C137	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327	
	C138	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677	
	C139	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179	
	C140	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 ; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C141	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	
	C142	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paraoxonase active site," Chem Biol Interact, Vol. 119-120:79-84	
	C143	JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis," Chem Biol Interact, Vol. 119-120:71-78	
	C144	JUBINSKY et al., 1996, "The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773	
	C145	JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor," Blood 90(5):1867-1873	
	C146	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury," Proc. Natl. Acad. Sci. USA 99(16):10659-10664	
	C147	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system," Pediatr. Res. 43(1):40-49	
	C148	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus," Early Human Devel. 52(3):235-249	
	C149	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep," Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001)	
	C150	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage," Acta Paediatr. Supp. Vol. 438, pp. 36-42	
	C151	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor," Drug Metab Dispos. Vol. 22(1):99-105	
	C152	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin," Glycobiology, Vol. 11(12):1043-1049	
	C153	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of heart failure-induced mitral regurgitation. Circulation 108:1795-1797	
	C154	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New York Acad. Sci., 149:18-24.	
	C155	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration," Ann. Neurol. Vol. 56(6):815-826	
	C156	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation," Blood 99(1):102-110	
	C157	KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver," Am J Anat. Vol. 178:241-9.	
	C158	KITAJIMA et al., 1994, "Effective combination therapy by recombinant erythropoietin and cepharanthin in a girl with refractory anemia," Japanese J. Clin. Hematology. Vol. 35(7):694-6988 (w/English abstract)	
	C159	KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," Blood. Vol 73(2):375-80	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C160	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96(5):826-828.	
	C161	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons <i>in vitro</i> and <i>in vivo</i> ", Brain Res. 609:29-35	
	C162	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C163	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," J of Trauma, Vol. 44(2):361-367	
	C164	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86	
	C165	KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle cerebral artery occlusion," Acta Neurophologica, Vol. 68:122-129	
	C166	LAI et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93:231-235	
	C167	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31(4):601-608	
	C168	LEE P et al. 1998, Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A. 95:11371-11376	
	C169	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol. 305, pp. 239-242	
	C170	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol. 93:75-80	
	C171	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation <i>in vitro</i> ," Exp. Hematol. 32:36-44	
	C172	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40(3):376-380	
	C173	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85(3):785-794	
	C174	LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund, http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004	
	C175	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," Anal. Biochem. 219:207-217	
	C176	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C177	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935	
	C178	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C179	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression". Proc. Assoc. Am. Physicians 108(6):449-454	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE May 30, 2006	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C180	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400	
	C181	LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413	
	C182	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990	
	C183	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783	
	C184	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C185	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017	
	C186	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874	
	C187	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C188	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C189	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C190	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C191	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8	
	C192	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216	
	C193	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493	
	C194	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C195	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C196	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476	
	C197	McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243	
	C198	MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208	
	C199	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?, Ann. R. Coll. Surg. Engl., Vol. 72:60-3	
	C200	MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl.	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Vol. 51:220-222	
	C201	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C202	MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994	
	C203	MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229	
	C204	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564.	
	C205	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390	
	C206	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid-Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159.	
	C207	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C208	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C209	MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7	
	C210	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353	
	C211	MURRAY, 1996, Harpers Illustrated Biochemistry 26 th ed. pp. 524-526, McGraw-Hill Co., .	
	C212	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897	
	C213	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201	
	C214	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302	
	C215	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35	
	C216	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethane," J. Biol Chem. Vol. 260(12):7316-21	
	C217	NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoietin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7	
	C218	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C219	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31	
	C220	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE May 30, 2006	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C221	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15	
	C222	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11	
	C223	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	
	C224	ON-LINE MEDICAL DICTIONARY Lysozyme entry; website http://cancerweb.ncl.ac.uk/omd . Published at the Dept. of Medical Oncology, University of Newcastle upon Tyne. Copyright 1997-2004. The CancerWEB Project.	
	C225	OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261	
	C226	OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267	
	C227	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69	
	C228	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082	
	C229	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60	
	C230	Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92.	
	C231	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731	
	C232	PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704	
	C233	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635	
	C234	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16	
	C235	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773	
	C236	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980	
	C237	PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropathol Exp Neurol. Vol. 38(3):222-34	
	C238	PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414	
	C239	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C240	PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769	
	C241	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-720	
	C242	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C243	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C244	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091	
	C245	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-352	
	C246	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176	
	C247	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8	
	C248	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993	
	C249	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C250	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253	
	C251	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030	
	C252	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51	
	C253	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842	
	C254	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452	
	C255	SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C256	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188	
	C257	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C258	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C259	SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37	
	C260	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74(1):103-109	
	C261	SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100	
	C262	SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift fur Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only)	
	C263	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590	
	C264	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464	
	C265	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C266	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C267	SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107	
	C268	SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169	
	C269	SIREN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049	
	C270	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29	
	C271	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C272	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C273	STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594	
	C274	STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866	
	C275	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C276	STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C277	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C278	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C279	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: I. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neuropathologica (Berl), Vol. 60:207-216	
	C280	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C281	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535	
	C282	SWISS ACCESSION No. P32927, October 1, 1993	
	C283	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516	
	C284	SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3867-3872	
	C285	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. Vol. 13(3/4):241-252	
	C286	TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402	
	C287	TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J Am Coll Cardiol. 25(1): 264-268	
	C288	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738	
	C289	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448	
	C290	URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale, Vol. 31(11):505-514 (Abstract only)	
	C291	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infraction," JACC, Vol. 46(11) pp. 125-133	
	C292	VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508	
	C293	VEZANNI et al., 1999, "Interleukin-1- β Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci, Vol 19(12):5054-65	
	C294	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol Exp. Ther, Vol 239(1):256-63	
	C295	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," PNAS USA, Vol. 93:9021-9026	
	C296	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol Reprod. Vol. 38:1105-13.	
	C297	WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," Blut, 44:173-175.	
	C298	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry, Vol. 29(37):8509-8517	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C299	WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846	
	C300	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C301	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70	
	C302	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C303	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344	
	C304	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30	
	C305	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-I-42	
	C306	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958	
	C307	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485	
	C308	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509	
	C309	WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83	
	C310	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C311	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194	
	C312	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C313	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C314	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C315	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38	
	C316	YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C317	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C318	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C319	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction,"	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905
	APPLICANT Coleman et al.	
	FILING DATE May 30, 2006	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Oncologist 1(5):337-339	
	C320	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7	
	C321	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51	
	C322	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C323	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C324	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C325	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C326	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C327	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C328	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C329	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	
	C330	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
	C331	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	
	C332	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	
	C333	Office Action, Application No. 09/718,829, date mailed: May 13, 2002	
	C334	Office Action, Application No. 09/718,829, date mailed: March 5, 2003	
	C335	Office Action, Application No. 09/718,829, date mailed: January 6, 2004	
	C336	Office Action, Application No. 09/718,829, date mailed: September 29, 2004	
	C337	Office Action, Application No. 09/718,829, date mailed: April 5, 2005	
	C338	Office Action, Application No. 09/718,829, date mailed: January 20, 2006	
	C339	Office Action, Application No. 09/718,829, date mailed: May 14, 2007	
	C340	Office Action, Application No. 09/718,829, date mailed: February 28, 2008	
	C341	Office Action, Application No. 09/716,963, date mailed: May 17, 2002	
	C342	Office Action, Application No. 09/716,963, date mailed: February 10, 2003	
	C343	Office Action, Application No. 09/716,963, date mailed: October 17, 2003	
	C344	Office Action, Application No. 09/716,963, date mailed: July 28, 2004	
	C345	Office Action, Application No. 09/716,963, date mailed: November 23, 2004	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C346	Office Action, Application No. 09/716,963, date mailed: March 18, 2005	
	C347	Office Action, Application No. 09/716,963, date mailed: December 7, 2005	
	C348	Office Action, Application No. 09/716,963, date mailed: July 21, 2006	
	C349	Office Action, Application No. 09/716,963, date mailed: March 13, 2007	
	C350	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C351	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C352	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C353	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C354	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C355	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C356	Office Action, Application No. 09/716,960, date mailed: February 1, 2007	
	C357	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
	C358	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	
	C359	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C360	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C361	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C362	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C363	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C364	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C365	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C366	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C367	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C368	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C369	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C370	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C371	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C372	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C373	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Express Mail No.: EV 654 895 272 USExpress Mail No.: EV 654 895 286 USExpress Mail No.: EV 654 895 290 USExpress Mail No.: EV 654 895 309 US

Sheet 25 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-042-999	10/573,905
	APPLICANT	
	Coleman et al.	
	FILING DATE	ART UNIT
	May 30, 2006	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C374	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	
	C375	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	
	C376	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	
	C377	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	
	C378	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	
	C379	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C380	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	
	C381	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C382	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C383	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C384	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C385	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
	C386	Office Action, Application No. 10/188,905, date mailed: January 8, 2008	
	C387	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	
	C388	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	
	C389	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	
	C390	Office Action, Application No. 10/351,640, date mailed: March 19, 2008	
	C391	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	
	C392	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	
	C393	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	
	C394	Office Action, Application No. 10/676,694, date mailed: May 31, 2007	
	C395	Office Action, Application No. 10/520,140, date mailed: October 3, 2005	
	C396	Office Action, Application No. 10/520,140, date mailed: June 19, 2006	
	C397	Office Action, Application No. 10/520,140, date mailed: March 28, 2007	
	C398	Office Action, Application No. 10/520,140, date mailed: December 27, 2007	
	C399	LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL	
	C400	NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975	

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 26 of 26 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 10165-042-999	APPLICATION NO. 10/573,905
	APPLICANT Coleman et al.	
	FILING DATE May 30, 2006	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C401	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and commom β -subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912	
	C402	Office Action, Application No. 10/185,841, date mailed: May 23, 2008	

EXAMINER NYI-4088719v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	